An experimental drug poised to become the world's leading treatment for multiple sclerosis got investors excited about this Massachusetts-based drug-maker. Shares of Biogen Idec surged after studies showed the effectiveness of BG-12, which analysts estimate could generate up to $3 billion in annual sales.
Under relatively new CEO George Scangos, Biogen reported robust earnings. For 2011, profits rose by 23% to $1.23 billion or $5.04 per share. And Scangos was handsomely rewarded for that performance. He earned $11.3 million in salary, bonus and stock awards.
|Military retirees: You betrayed us, Congress|
|I work 4 jobs and I'm still struggling|
|Instagram launches direct messaging|
|Apple supplier draws scrutiny after worker deaths|
|Don't fight it. Bitcoin has a bright future|
Investors in these Fortune 500 companies saw devastating losses